Skip to main content

Table 3 Association of combined expression status of SIRT1 and N1IC with clinicopathological parameters

From: Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer

Characteristics

N

SIRT1/N1IC

  

High/low

Low/low

High/high

Low/high

χ 2

p- value

  

N (%)

N (%)

N (%)

N (%)

  

Age (years)

       

   <50

74

12 (16.2)

1 (1.4)

44 (59.4)

17 (23.0)

6.027

0.110

  ≥50

76

22 (28.9)

4 (5.3)

37 (48.7)

13 (17.1)

Lymph node metastasis

       

  Absence

83

18 (21.7)

4 (4.8)

48 (57.8)

13 (15.7)

3.664

0.300

  Presence

67

16 (23.9)

1 (1.5)

33 (49.3)

17 (25.4)

TNM stage

       

  I-III

128

30 (23.4)

4 (3.1)

69 (53.9)

25 (19.5)

0.441

0.932

  IV

22

4 (18.2)

1 (4.5)

12 (54.5)

5 (22.7)

Histological grade

       

  1 + 2

102

18 (17.6)

4 (3.9)

55 (53.9)

25 (24.5)

7.334

0.062

  3

48

16 (33.3)

1 (2.1)

26 (54.2)

5 (10.4)

  

ER status

       

  Negative

71

17 (23.9)

2 (2.8)

33 (46.5)

19 (26.8)

4.728

0.193

  Positive

79

17 (21.5)

3 (3.8)

48 (60.8)

11 (13.9)

PR status

       

  Negative

71

17 (23.9)

2 (2.8)

36 (50.7)

16 (22.5)

0.910

0.823

  Positive

79

17 (21.5)

3 (3.8)

45 (57.0)

14 (17.7)

HER2 status

       

  Negative

111

28 (25.2)

4 (3.6)

52 (46.8)

27 (24.3)

10.052

0.018*

  Positive

39

6 (15.4)

1 (2.6)

29 (74.4)

3 (7.7)

Adjuvant therapy

       

  Chemo

75

17 (22.7)

2 (2.7)

43 (57.3)

13 (17.3)

17.431

0.042*

  Chemo + radio

15

2 (13.3)

1 (6.7)

7 (46.7)

5 (33.3)

  Chemo + radio + endocrine

12

2 (16.7)

1 (8.3)

2 (16.7)

7 (58.3)

  Unknown

48

13 (27.1)

1 (2.1)

29 (60.4)

5 (10.4)

  1. Chemo: chemotherapy; Radio: radiotherapy; Endo: endocrine therapy; N: number of patients; *P < 0.05.